'Medical AI that makes money' proven by US company… JLK expected to see revenue turnaround
Predicted impact: Low
Vague hope of revenue turnaround based on a US peer; no concrete company event.
JLK제이엘케이
322510 · KOSDAQ · ₩322510 · 제이엘케이
₩4,840▲ ₩5 (0.10%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −19.20%
- Market cap
- ₩125B
- Enterprise value
- ₩114B
- P/E
- —
- P/B
- 3.6×
- Dividend yield
- 0.0%
- ROE
- −43.6%
- Net margin
- −555.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−47.4% from the high
₩3,765Today: ₩4,805 – ₩4,965₩9,210
Returns
- 1W−0.9%
- 1M−5.5%
- 3M+7.2%
- 6M−35.5%
- YTD−12.9%
- 1Y−19.2%
- Volume today
- 44,303
- 0.5× the 20-day average
- Traded today
- ₩215M
- Listed shares
- 25,725,892
- EPS (12 months)
- −₩588
- Earnings yield −12.1%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 33 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Headline points to an expected revenue turnaround and a positive view of medical AI. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat0.8% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
JLK stock overview
JLK (제이엘케이, KRX: 322510) is listed on KOSDAQ, in the Software sector. The company develops medical artificial intelligence solutions that analyze medical imaging and clinical data to support early disease diagnosis, image reading, lesion detection, and prognosis prediction. Its shares closed at ₩4,840 on Oct 28, 2026, up 0.10% on the day, giving it a market value of ₩125B.
Key facts
- Market cap
- ₩125B
- Sector
- Software
- Latest price change
- +0.10%
- As of
- Oct 28, 2026
- Main business
- The company develops medical artificial intelligence solutions that analyze medical imaging and clinical data to support early disease diagnosis, image reading, lesion detection, and prognosis prediction.
Quick answers about JLK
- What does JLK do?
- The company develops medical artificial intelligence solutions that analyze medical imaging and clinical data to support early disease diagnosis, image reading, lesion detection, and prognosis prediction. Its core offering is MEDIHUB STROKE, a suite of 12 AI solutions for stroke across the full course of care, used by large hospitals and increasingly by smaller clinics, and it also offers cancer analysis solutions such as the prostate cancer solution JPC-01K. The company sells in South Korea and is expanding into the United States and Japan, where several of its solutions hold FDA 510(k) clearance and PMDA approval.
- What is the market cap of JLK?
- The market capitalisation of JLK was ₩125B at the close on Oct 28, 2026.
- Who are the largest shareholders of JLK?
- According to the latest official filings, the largest reported holders are Kim Won-tae (21.18%, as of Jul 31, 2026); KB Asset Management (6.56%, as of Oct 2, 2026); National Pension Service (3.36%, as of Dec 31, 2024).
- When is the next earnings report from JLK?
- Korean companies rarely announce results dates in advance. Based on when JLK filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own JLK?
- Yes. The National Pension Service held 3.36% of JLK shares as of Dec 31, 2024.
Company profile
The company develops medical artificial intelligence solutions that analyze medical imaging and clinical data to support early disease diagnosis, image reading, lesion detection, and prognosis prediction. Its core offering is MEDIHUB STROKE, a suite of 12 AI solutions for stroke across the full course of care, used by large hospitals and increasingly by smaller clinics, and it also offers cancer analysis solutions such as the prostate cancer solution JPC-01K. The company sells in South Korea and is expanding into the United States and Japan, where several of its solutions hold FDA 510(k) clearance and PMDA approval.
Written by AI from the company's latest annual report.
- Korean name
- 제이엘케이
- Sector
- Software
- Themes
- AI healthcare
- CEO
- 김동민
- Founded
- Feb 2014
- Listed
- Dec 2019
- Listed shares
- 25,725,892
- Fiscal year ends
- Month 12
- Website
- jlkgroup.com
Similar companies
- Hyundai Autoever307950 · ₩9.6T₩350,000+7.53%
- Krafton259960 · ₩8.4T₩183,200+0.38%
- NC036570 · ₩4.3T₩201,000+1.16%
- Netmarble251270 · ₩2.8T₩33,550−0.30%
- PearlAbyss263750 · ₩2.1T₩34,200+0.44%
- Shift UP462870 · ₩1.7T₩29,300−0.85%
- NHN181710 · ₩1.6T₩49,000−1.71%
- Ahnlab053800 · ₩1.2T₩110,900+19.63%
Recent news
Recent filings
See all- 5%+ holding reportOct 2, 2026
- Results of Extraordinary Shareholders' MeetingAug 14, 2026
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsAug 14, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportJul 31, 2026
Titles in Korean until English translations are added.
Also known as: JLK / 제이엘케이 / 322510 / KRX:322510
Source: KRX statistical information